At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Sep 3, 2026 at 19:30 ET
Biogen (BIIB) and partner Stoke Therapeutics (STOK) presented positive 4-year open-label extension data for zorevunersen in Dravet syndrome at the European Epilepsy Congress, showing durable seizure reductions and cognitive/behavioral improvements. The Phase 3 EMPEROR study data readout is anticipated in Q3 2027, with a rolling NDA submission planned for H2 2027. This is a clinical update with no financial terms disclosed, and the stock-moving catalyst remains the Phase 3 results over a year away.
- 4-year OLE data showed 93% (75/81) of eligible patients continued treatment; 77% (58/75) remained at data cutoff
- Statistically significant improvements in cognition and behavior at 1, 2, 3, and 4 years vs OLE baseline
- Substantial reductions in generalized tonic-clonic and focal-to-bilateral tonic-clonic seizures through 3 years
- Quality of life improvements demonstrated through 28 months via EQ-VAS
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access